These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 25455883)

  • 1. Cost-effectiveness of PET and PET/computed tomography: a systematic review.
    Gerke O; Hermansson R; Hess S; Schifter S; Vach W; Høilund-Carlsen PF
    PET Clin; 2015 Jan; 10(1):105-24. PubMed ID: 25455883
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness analysis of routine surveillance imaging of patients with diffuse large B-cell lymphoma in first remission.
    Huntington SF; Svoboda J; Doshi JA
    J Clin Oncol; 2015 May; 33(13):1467-74. PubMed ID: 25823735
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness analysis in the clinical management of patients with known or suspected lung cancer: [18F]fluorodeoxyglucose PET and CT comparison.
    Mansueto M; Grimaldi A; Torbica A; Pepe G; Giovacchini G; Messa C; Fazio F
    Q J Nucl Med Mol Imaging; 2007 Sep; 51(3):224-34. PubMed ID: 17538525
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness analysis of 18F-FDG PET/CT in detecting suspected recurrence or metastasis in well-differentiated thyroid carcinoma patients with negative diagnostic total body scan in Thailand: a decision analysis.
    Khiewvan B; Nopmaneejumruslers C; Pusuwan P; Tuchinda P; Tojinda N; Ubolnuch K
    J Med Assoc Thai; 2013 Oct; 96(10):1350-64. PubMed ID: 24350419
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of FDG-PET/CT for cytologically indeterminate thyroid nodules: a decision analytic approach.
    Vriens D; Adang EM; Netea-Maier RT; Smit JW; de Wilt JH; Oyen WJ; de Geus-Oei LF
    J Clin Endocrinol Metab; 2014 Sep; 99(9):3263-74. PubMed ID: 24873995
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [18FDG-PET/CT cost-effectiveness compared to CT at the end of treatment in pediatric Hodgkin's lymphoma patients].
    García-Molina M; Chicaíza-Becerra L; Moreno-Calderon A; Prieto-Martínez V; Sarmiento-Urbina I; Linares-Ballesteros A
    Rev Salud Publica (Bogota); 2014; 16(2):260-9. PubMed ID: 25383499
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PET-CT in oncological patients: analysis of informal care costs in cost-benefit assessment.
    Orlacchio A; Ciarrapico AM; Schillaci O; Chegai F; Tosti D; D'Alba F; Guazzaroni M; Simonetti G
    Radiol Med; 2014 Apr; 119(4):283-9. PubMed ID: 24277511
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A systematic review of PET and PET/CT in oncology: a way to personalize cancer treatment in a cost-effective manner?
    Langer A
    BMC Health Serv Res; 2010 Oct; 10():283. PubMed ID: 20932288
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Analysis of cost-effectiveness in the diagnosis of fever of unknown origin and the role of (18)F-FDG PET-CT: a proposal of diagnostic algorithm].
    Becerra Nakayo EM; García Vicente AM; Soriano Castrejón AM; Mendoza Narváez JA; Talavera Rubio MP; Poblete García VM; Cordero García JM
    Rev Esp Med Nucl Imagen Mol; 2012; 31(4):178-86. PubMed ID: 23067686
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of routine (18)F-FDG PET/CT in high-risk patients with gram-positive bacteremia.
    Vos FJ; Bleeker-Rovers CP; Kullberg BJ; Adang EM; Oyen WJ
    J Nucl Med; 2011 Nov; 52(11):1673-8. PubMed ID: 21984799
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ¹⁸F-FDG PET/CT in inflammation of unknown origin: a cost-effectiveness pilot-study.
    Balink H; Tan SS; Veeger NJ; Holleman F; van Eck-Smit BL; Bennink RJ; Verberne HJ
    Eur J Nucl Med Mol Imaging; 2015 Aug; 42(9):1408-13. PubMed ID: 25655485
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 18FDG-PET-CT in the follow-up of non-small cell lung cancer patients after radical radiotherapy with or without chemotherapy: an economic evaluation.
    van Loon J; Grutters JP; Wanders R; Boersma L; Dingemans AM; Bootsma G; Geraedts W; Pitz C; Simons J; Brans B; Snoep G; Hochstenbag M; Lambin P; De Ruysscher D
    Eur J Cancer; 2010 Jan; 46(1):110-9. PubMed ID: 19944595
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A prospective evaluation of the utility of 2-deoxy-2-[(18) F]fluoro-D-glucose positron emission tomography and computed tomography in staging locally advanced gastric cancer.
    Smyth E; Schöder H; Strong VE; Capanu M; Kelsen DP; Coit DG; Shah MA
    Cancer; 2012 Nov; 118(22):5481-8. PubMed ID: 22549558
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness analysis of FDG PET-CT in the management of pulmonary metastases from malignant melanoma.
    Krug B; Crott R; Roch I; Lonneux M; Beguin C; Baurain JF; Pirson AS; Vander Borght T
    Acta Oncol; 2010; 49(2):192-200. PubMed ID: 20059314
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The cost-utility analysis of 18-fluoro-2-deoxyglucose positron emission tomography in the diagnosis of recurrent nasopharyngeal carcinoma.
    Yen RF; Yen MF; Hong RL; Tzen KY; Chien CR; Chen TH
    Acad Radiol; 2009 Jan; 16(1):54-60. PubMed ID: 19064212
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness analysis of strategies introducing integrated ¹⁸F-FDG PET/CT into the mediastinal lymph node staging of non-small-cell lung cancer.
    Han Y; Xiao H; Zhou Z; Yuan M; Zeng Y; Wu H; Fang Y
    Nucl Med Commun; 2015 Mar; 36(3):234-41. PubMed ID: 25460305
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of adding FDG-PET or CT to the diagnostic work-up of patients with stage III melanoma.
    Bastiaannet E; Uyl-de Groot CA; Brouwers AH; van der Jagt EJ; Hoekstra OS; Oyen W; Verzijlbergen F; van Ooijen B; Thompson JF; Hoekstra HJ
    Ann Surg; 2012 Apr; 255(4):771-6. PubMed ID: 22367443
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Consistency of FDG-PET accuracy and cost-effectiveness in initial staging of patients with Hodgkin lymphoma across jurisdictions.
    Cerci JJ; Trindade E; Buccheri V; Fanti S; Coutinho AM; Zanoni L; Linardi CC; Celli M; Delbeke D; Pracchia LF; Pitela FA; Soares J; Zinzani PL; Meneghetti JC
    Clin Lymphoma Myeloma Leuk; 2011 Aug; 11(4):314-20. PubMed ID: 21816369
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Cost analysis of18F-FDG PET-CT from the perspective of the Brazilian Unified National Health System as healthcare provider: a study in a public healthcare center in Rio de Janeiro, Brazil].
    Caetano R; Schluckebier LF; Bastos CR; Silva RM; Carneiro MP; Silva JW; Biz AN
    Cad Saude Publica; 2014 Feb; 30(2):379-92. PubMed ID: 24627065
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PET/CT in non-small cell lung cancer staging-promises and problems.
    Devaraj A; Cook GJ; Hansell DM
    Clin Radiol; 2007 Feb; 62(2):97-108. PubMed ID: 17207691
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.